PDCD1 and cancer: Furthermore, C/EBPβ KO could promote chemokine expression in multiple types of cancer cells, thus potentially enhancing the sensitivity of programmed cell death protein 1 (PD-1) antibody (Ab)–mediated cancer immunotherapy.